COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder

NASDAQ Market News

NEXT STORY
Polymerase Chain Reaction Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)
PREV STORY
Global Automated Liquid Handlers Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor

PLYMOUTH MEETING, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...

author_avatar
NASDAQ Market News

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children ...

author_avatar
NASDAQ Market News

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

author_avatar
NASDAQ Market News